Evidence map›Paper›PMID 41880193›Full record

ArticleThe Journal of experimental medicine2026

MYCT1-IFITM2/3 interaction links endothelial endolysosomal trafficking to white adipose tissue expansion.

Laureline Wetterwald, Anna Köck, Tania Wyss, Silvia Arroz-Madeira, Borja Prat-Luri, Muriel Jaquet, Benoît Petit, Marie-Catherine Vozenin, Seppo Ylä-Herttuala, Valérie Dutoit and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Laureline Wetterwald *Department of Fundamental Oncology, University of Lausanne, Lausanne, Switzerland.ORCID 0000-0001-7935-743X
Anna Köck *Department of Fundamental Oncology, University of Lausanne, Lausanne, Switzerland.ORCID 0009-0003-1637-0719
Tania WyssDepartment of Fundamental Oncology, University of Lausanne, Lausanne, Switzerland.ORCID 0000-0003-2641-0895
Silvia Arroz-MadeiraDepartment of Fundamental Oncology, University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-2456-9977
Borja Prat-LuriDepartment of Fundamental Oncology, University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-6120-1370
Muriel JaquetDepartment of Fundamental Oncology, University of Lausanne, Lausanne, Switzerland.ORCID 0009-0006-7332-9642
Benoît PetitDepartment of Fundamental Oncology, University of Lausanne, Lausanne, Switzerland.ORCID 0009-0003-9397-4583
Marie-Catherine VozeninDepartment of Fundamental Oncology, University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-2109-8073
Seppo Ylä-HerttualaA.I. Virtanen Institute for Molecular Sciences, Faculty of Health Sciences, University of Eastern Finland , Kuopio, Finland.ORCID 0000-0001-7593-2708
Valérie DutoitBrain Tumor and Immune Cell Engineering Laboratory and Center for Translational Research in Onco-Hematology, University of Geneva , Geneva, Switzerland.ORCID 0000-0002-3469-4237
Denis MiglioriniBrain Tumor and Immune Cell Engineering Laboratory and Center for Translational Research in Onco-Hematology, University of Geneva , Geneva, Switzerland.ORCID 0000-0003-0151-3222
Karin SchaeubleDepartment of Fundamental Oncology, University of Lausanne, Lausanne, Switzerland.ORCID 0000-0003-1826-0129
Cathrin BriskenISREC - Swiss Institute for Experimental Cancer Research, School of Life Sciences, EPFL , Lausanne, Switzerland; and The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.ORCID 0000-0002-6857-3230
Mauro DelorenziDepartment of Fundamental Oncology, University of Lausanne, Lausanne, Switzerland.ORCID 0000-0001-7631-3263
Amélie SabineDepartment of Fundamental Oncology, University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-7512-6703
Tatiana V PetrovaDepartment of Fundamental Oncology, University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-0563-6521

Funding

Alfred und Anneliese Sutter-Stöttner StiftungFondation Joseph et Lina SpicherFondation Pierre Mercier pour la ScienceHuman Frontier Science Program LT000633/2020-LKurt und Senta Herrmann StiftungNovartis Foundation 17C196Nuovo-Soldati Foundation for Cancer ResearchSwiss National Science Foundation 182637
6 · The paper itself

Abstract

Vertebrates rely on a network of blood vessels to meet organ demands for oxygen and nutrients. While endothelial cells are known to transport excess nutrients to white adipose tissue (WAT) for energy storage, how their metabolic state impacts this process remains unclear. Here, we identify MYCT1 as a conserved, pan-endothelial protein essential for WAT expansion. Endothelial-specific MYCT1 deletion limited WAT expansion independently of angiogenesis, adipogenesis, or systemic metabolic parameters. Mechanistically, MYCT1 interacted with the transmembrane endolysosomal proteins IFITM2/3 to restrict nutrient consumption by the vascular barrier. Loss of MYCT1 caused IFITM2/3 accumulation in early endosomes, promoting excessive endolysosomal degradation and mTORC1 hyperactivation, limiting the WAT energy storage capacity. Notably, endothelial-specific mTORC1 activation through TSC1 deletion phenocopied the fat storage defects of MYCT1 deficiency. Our findings establish the MYCT1-IFITM2/3 complex as endothelial metabolic checkpoint regulating systemic energy storage. Targeting MYCT1-IFITM2/3 may offer new therapeutic options for obesity and metabolic disorders.

Indexed as

Adipose Tissue, WhiteEndosomesEndothelial CellsLysosomesMembrane ProteinsAnimalsHumansMechanistic Target of Rapamycin Complex 1MiceMechanistic Target of Rapamycin Complex 1Membrane Proteins

Identifiers

PMID41880193
PMCPMC13016079

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.